Research Topics
| H L KindlerSummaryAffiliation: University of Chicago Country: USA Publications
| Collaborators
|
Detail Information
Publications
A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancerH L Kindler
Section of Hematology Oncology, University of Chicago Medical Center, Chicago, IL 60637, USA
Ann Oncol 23:2834-42. 2012....
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesotheliomaHedy L Kindler
University of Chicago ComprehensiveCancer Center, Chicago, IL, USA
J Clin Oncol 30:2509-15. 2012..We added the anti-VEGF antibody bevacizumab to gemcitabine/cisplatin in a multicenter, double-blind, placebo-controlled randomized phase II trial in patients with previously untreated, unresectable MM...- A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancerHedy Lee Kindler
University of Chicago, 5841 South Maryland Avenue, MC2115, Chicago, IL, 60637 1460, USA
Invest New Drugs 27:75-81. 2009..This phase II study was designed to evaluate the efficacy and safety of L-alanosine in patients with MTAP-deficient solid tumors... 
Front-line therapy of advanced pancreatic cancerHedy Lee Kindler
Section of Hematology Oncology, University of Chicago Cancer Research Center, Chicago, IL 60637, USA
Semin Oncol 32:S33-6. 2005..Agents that target vascular endothelial growth factor and the epidermal growth factor receptor are currently being evaluated in phase III trials...- Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group BHedy L Kindler
University of Chicago, 5841 S Maryland Avenue, MC 2115, Chicago, IL 60637, USA
Lung Cancer 48:423-8. 2005..The Cancer and Leukemia Group B (CALGB) conducted a multi-center phase II trial to evaluate the activity of irinotecan in malignant mesothelioma (CALGB protocol 9733)... - Phase I/II trial of gefitinib and oxaliplatin in patients with advanced colorectal cancerHedy Lee Kindler
University of Chicago Medical Center, Illinois 60637 1470, USA
Am J Clin Oncol 28:340-4. 2005..The authors conclude that the combination of gefitinib plus oxaliplatin is inactive in advanced colorectal cancer... - Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancersHedy L Kindler
Section of Hematology Oncology, University of Chicago Medical Center, 5841 South Maryland Avenue, Chicago, IL 60637, USA
Invest New Drugs 23:489-93. 2005..We conducted 2 parallel phase II trials of dolastatin-10 in patients with advanced hepatobiliary cancers and pancreatic adenocarcinoma... - Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancerHedy L Kindler
Section of Hematology Oncology, University of Chicago Medical Center, IL 60637, USA
J Clin Oncol 23:8033-40. 2005..The objectives of this phase II study were to assess the response rate and overall survival of pancreatic cancer patients who received gemcitabine with the recombinant humanized anti-VEGF monoclonal antibody bevacizumab... - Pancreatic cancer: an updateHedy Lee Kindler
Section of Hematology Oncology, University of Chicago, MC 2115, Chicago, IL 60637 1470, USA
Curr Oncol Rep 9:170-6. 2007..Several key negative studies have also been reported recently. This review discusses recent trials that have changed the standard of care for patients with advanced pancreatic cancer... - Systemic treatments for mesothelioma: standard and novelHedy Lee Kindler
Section of Hematology Oncology, University of Chicago, Chicago, IL 60637, USA
Curr Treat Options Oncol 9:171-9. 2008..Given the progress made in recent years, there is reason to believe that more effective treatments will continue to be developed... - Arsenic trioxide in patients with adenocarcinoma of the pancreas refractory to gemcitabine: a phase II trial of the University of Chicago Phase II ConsortiumHedy Lee Kindler
Section of Hematology Oncology, University of Chicago Medical Center, Chicago, IL 60637 1463, USA
Am J Clin Oncol 31:553-6. 2008..We conducted a multicenter phase II trial in patients with advanced pancreatic cancer who experienced disease progression on or after a gemcitabine-containing regimen... - Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303)Hedy Lee Kindler
University of Chicago Cancer Research Center, Chicago, IL 60637 1470, USA
J Clin Oncol 28:3617-22. 2010..These encouraging data led Cancer and Leukemia Group B (CALGB) to conduct a double-blind, placebo-controlled, randomized phase III trial of gemcitabine/bevacizumab versus gemcitabine/placebo in advanced pancreatic cancer patients... - Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 studyHedy L Kindler
University of Chicago Comprehensive Cancer Center, Chicago, IL 60637, USA
Lancet Oncol 12:256-62. 2011..On the basis of these results, we aimed to assess the effect of treatment with gemcitabine plus axitinib on overall survival in a phase 3 trial... - Moving beyond chemotherapy: novel cytostatic agents for malignant mesotheliomaHedy L Kindler
Department of Hematology Oncology, Medical Center, University of Chicago, 5841 South Maryland Avenue, MC 2115, IL 60637 1470, USA
Lung Cancer 45:S125-7. 2004..Two clinical trials are planned to evaluate the two PDGF inhibitors Gleevec (Imatinib mesylate, STI-571, Novartis Pharmaceuticals) and PTK787 (Novartis Pharmaceuticals)... - 9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortiumHedy L Kindler
Section of Hematology Oncology, University of Chicago, Chicago, IL, USA
Invest New Drugs 22:323-7. 2004..Grade 3 nausea and fatigue each developed in 7% of patients. We conclude that 9-AC given by 120-hour continuous infusion demonstrates no clinical activity in patients with metastatic gastric cancer... - The pemetrexed/gemcitabine combination in pancreatic cancerHedy Lee Kindler
Director of Gastrointestinal Oncology, Section of Hematology Oncology, University of Chicago, Chicago, Illinois 60637, USA
Cancer 95:928-32. 2002..The promising activity observed in this study has led to an ongoing international, randomized, Phase III trial in 520 patients comparing the pemetrexed/gemcitabine combination with gemcitabine alone... - Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II ConsortiumHedy Lee Kindler
Department of Medicine, Section of Hematology Oncology, University of Chicago, 5841 South Maryland Avenue, MC 2115, Chicago, IL 60637, USA
Invest New Drugs 30:382-6. 2012..Sorafenib, an inhibitor of B-raf, VEGFR2, and PDGFR-β, has activity against pancreatic cancer in preclinical models. In a phase I trial of gemcitabine plus sorafenib, 57% of pancreatic cancer patients achieved stable disease... - Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group BH L Kindler
University of Chicago Medical Center, 5841 S Maryland Avenue, Chicago, IL 60637, USA
Lung Cancer 31:311-7. 2001..The CALGB conducted a phase II multicenter trial to evaluate the activity of gemcitabine in malignant mesothelioma (CALGB protocol 9530)... - Metastatic colorectal cancerH L Kindler
Section of Hematology Oncology, University of Chicago Medical Center, 5841 S Maryland Avenue, MC 2115, Chicago, IL 60637, USA
Curr Treat Options Oncol 2:459-71. 2001..The emergence of these new drugs and new interventional modalities has allowed physicians who treat colorectal cancer to move beyond 5-FU... - A phase II trial of the epothilone B analog, BMS-247550, in patients with previously treated advanced colorectal cancerC Eng
Department of Medicine, Section of Hematology Oncology, University of Chicago, IL 60612, USA
Ann Oncol 15:928-32. 2004..We conducted a phase II study of single-agent BMS-247550 in advanced colorectal cancer patients who had disease progression following treatment with irinotecan-5-fluorouracil-leucovorin (IFL)... - Oral fluoropyrimidine treatment of colorectal cancerC Eng
Section of Hematology Oncology, University of Chicago Medical Center, 5841 S Maryland Avenue, MC 2115, USA
Clin Colorectal Cancer 1:95-103. 2001..The goal of this article is to review the features of the main oral 5-FU prodrugs, which include capecitabine, uracil and tegafur (UFT)/leucovorin, S-1, and BOF-A2 and to describe their potential efficacy in treating colorectal cancer... - Phase II trial of gemcitabine in patients with previously untreated metastatic cancer of the esophagus or gastroesophageal junctionA B Sandler
Department of Medicine, Indiana University, Indianapolis, USA
Ann Oncol 11:1161-4. 2000.... - A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabineS D Undevia
Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA
Ann Oncol 15:1705-11. 2004..CONCLUSIONS: The recommended phase II dose is 6 mg/m2 (or 10 mg) of CI-994 in combination with capecitabine 2000 mg/m2/day for 2 weeks of a 3-week cycle... - A Phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree carcinomaCathy Eng
Department of Medicine, Section of Hematology Oncology, University of Chicago, Chicago, IL, USA
Am J Clin Oncol 27:565-9. 2004..Grade 3/4 nonhematologic toxicities were minimal. We conclude that fixed dose rate gemcitabine results in significant myelosuppression and has minimal activity in patients with biliary tree carcinoma... - Phase II study of flavopiridol in patients with advanced colorectal cancerM Aklilu
Department of Medicine, University of Chicago, Chicago, IL, USA
Ann Oncol 14:1270-3. 2003..Trials that evaluate flavopiridol in combination with active cytotoxic drugs should help to define the role of this novel agent in ACRC... - Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenaseR L Schilsky
Biological Sciences Division, University of Chicago Medical Center, 5841 S Maryland Avenue, MC 2115, Chicago, IL 60637, USA
Expert Opin Investig Drugs 9:1635-49. 2000..Eniluracil is a promising drug, which permits reliable and safe administration of oral 5-FU and has the potential to overcome 5-FU resistance mediated by overexpression of DPD... - A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumoursSamir D Undevia
Department of Medicine, Section of Hematology Oncology, University of Chicago, Chicago, IL 60637, USA
Eur J Cancer 44:1684-92. 2008..Preclinical studies suggested that efficacy was independent of schedule but that toxicity was decreased by dividing the dose... - Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancerRichard L Schilsky
Department of Medicine, Section of Hematology Oncology, Cancer Research Center and Committee on Clinical Pharmacology, University of Chicago, Chicago, IL 60637, USA
J Clin Oncol 20:582-7. 2002..The goals of this phase I study were to determine the maximum-tolerated doses of capecitabine and gemcitabine in patients with advanced cancer and to describe the dose-limiting toxicities (DLT) and safety profile of this combination... - Current state and future directions of pleural mesothelioma imagingSamuel G Armato
Department of Radiology, The University of Chicago, 5841 S Maryland Ave, MC 2026, Chicago, IL 60637, USA
Lung Cancer 59:411-20. 2008..From diagnosis to response, PET/CT to molecular bioprobes, volumetric analysis to computerized tumor assessment, imaging promises to provide valuable insight for patients with mesothelioma and the physicians who treat them... - A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903Mitchell C Posner
University of Chicago, 5841 S Maryland Avenue MC5031, Chicago 60637, IL, USA
Ann Surg Oncol 15:158-64. 2008.... - Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapyLoren K Mell
Department of Radiation and Cellular Oncology, University of Chicago and University of Illinois at Chicago, Chicago, IL 60637, USA
Int J Radiat Oncol Biol Phys 70:1431-7. 2008.... - Computerized segmentation and measurement of malignant pleural mesotheliomaWilliam F Sensakovic
Department of Radiology, The University of Chicago, 5841 South Maryland Avenue, Chicago, Illinois 60637, USA
Med Phys 38:238-44. 2011..This manuscript presents a computerized method for the three-dimensional segmentation and volumetric analysis of MPM... - The cancer and leukemia group B respiratory committeeEverett E Vokes
The University of Chicago, Chicago, Illinois, USA
Clin Cancer Res 12:3581s-8s. 2006..We look forward to making additional critical contributions during future decades of Cancer and Leukemia Group B Respiratory Committee research... - Variability in mesothelioma tumor response classificationSamuel G Armato
Department of Radiology, The University of Chicago, 5841 S Maryland Ave, Chicago, IL 60637, USA
AJR Am J Roentgenol 186:1000-6. 2006..In addition, the performance of a semiautomated measurement method was evaluated... - Measurement of mesothelioma on thoracic CT scans: a comparison of manual and computer-assisted techniquesSamuel G Armato
Department of Radiology, The University of Chicago, 5841 South Maryland Avenue, Chicago, Illinois 60637, USA
Med Phys 31:1105-15. 2004..93). We have developed computerized techniques for the measurement of mesothelioma tumor thickness in CT scans. These techniques achieved varying levels of agreement with measurements made by human observers... - Evaluation of semiautomated measurements of mesothelioma tumor thickness on CT scansSamuel G Armato
Department of Radiology, The University of Chicago, 5841 South Maryland Avenue, Chicago, IL 60637, USA
Acad Radiol 12:1301-9. 2005..To evaluate the clinical acceptability of semiautomated methods for the measurement of mesothelioma tumor thickness in computed tomography (CT) scans... - Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancerSridhar Mani
Department of Medicine, Section of Hematology Oncology, Cancer Research Center, University of Chicago, Chicago, Illinois 60637, USA
Clin Cancer Res 8:1042-8. 2002..Our study warrants further exploration of efficacy in a Phase II and/or Phase III clinical trial setting... - Modulation of irinotecan with cyclosporine: a phase II trial in advanced colorectal cancerApurva A Desai
Section of Hematology Oncology, University of Chicago, 5841 S Maryland Avenue, MC 2115, Chicago, IL 60637, USA
Cancer Chemother Pharmacol 56:421-6. 2005..Hence, we conducted this phase II trial in patients with colorectal cancer (CRC) to further evaluate the toxicity and activity of irinotecan modulated with cyclosporine... - Personalized colon cancer care in 2010Daniel V T Catenacci
Department of Medicine, The University of Chicago, Chicago, IL 60637, USA
Semin Oncol 38:284-308. 2011..We then review strategies that will potentially improve our ability to individualize therapy in the future... - Quantitative measurement of lung reexpansion in malignant pleural mesothelioma patients undergoing pleurectomy/decorticationWilliam F Sensakovic
Department of Radiology, The University of Chicago, 5841 S Maryland Ave, Chicago, IL 60637, USA
Acad Radiol 18:294-8. 2011.... - Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignanciesChristopher W Ryan
Section of Hematology Oncology, Department of Medicine, Cancer Research Center, and Committee on Clinical Pharmacology and Pharmacogenomics, University of Chicago, Chicago, and Abbott Laboratories, Abbott Park, Illinois, USA
Clin Cancer Res 10:4406-11. 2004..This Phase I study sought to determine the toxicity and pharmacokinetics of daily atrasentan in a population of both female and male subjects with advanced malignancies... - Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I studyCharles M Rudin
The University of Chicago, Chicago, Illinois, USA
Clin Cancer Res 10:7244-51. 2004..Liposomal formulation may promote better intratumoral AON delivery and inhibit degradation in vivo. We conducted the first clinical evaluation of this concept using a liposomal AON complementary to the c-raf-1 proto-oncogene (LErafAON)... - Protein kinase C beta in malignant pleural mesotheliomaLeonardo Faoro
Section of Hematology Oncology, Department of Medicine, University of Chicago Pritzker School of Medicine, Chicago, Illinois 60637 1470, USA
Anticancer Drugs 19:841-8. 2008..Enzastaurin has preclinical activity against MPM, and exhibited synergism with cisplatin. PKCbeta inhibition in MPM might be able to reduce the invasiveness of MPM by affecting cytoskeletal function... - A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumorsPaul R Helft
University of Chicago, Chicago, Illinois, USA
Clin Cancer Res 10:4363-8. 2004..The evidence of antitumor activity suggests that additional clinical development is warranted, with a focus on tumors that express high levels of CanAg and which are known to be sensitive to antimicrotubule agents... - Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesotheliomaRamasamy Jagadeeswaran
Section of Hematology/Oncology, Department of Medicine, University of Chicago Cancer Research Center, University of Chicago Medical Center, Pritzker School of Medicine, Chicago, Illinois 60637, USA
Cancer Res 66:352-61. 2006..Ultimately, c-Met would be an important target for therapy against MPM... - A review of resistance patterns and phenotypic changes in gastrointestinal stromal tumors following imatinib mesylate therapyKai Bickenbach
Department of Surgery, University of Chicago Pritzker School of Medicine, 5841 S Maryland Avenue, Chicago, IL 60637, USA
J Gastrointest Surg 11:758-66. 2007..We highlight this review with an interesting case report that illustrates unique phenotypic tumoral changes associated with imatinib mesylate resistance... - The emerging role of pemetrexed for the treatment of malignant mesotheliomaHedy Lee Kindler
University of Chicago, Chicago, Illinois 60637-1463, USA
Oncology (Williston Park) 18:49-53. 2004..Additional trials are evaluating pemetrexed in the neoadjuvant setting and in combination with other cytotoxic and targeted agents... - New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agentsAnna K Nowak
University Department of Medicine, University of Western Australia, Verdun St Nedlands, Australia
Semin Oncol 29:82-96. 2002..The development of more active cytotoxic combinations in this disease should facilitate further studies of chemoimmunotherapy. It seems likely that no single treatment modality will be effective by itself... - In focus: advanced pancreatic cancerHedy Lee Kindler
University of Chicago, Chicago, IL 60637, USA
Clin Adv Hematol Oncol 3:420-2. 2005 - The role of gemcitabine in the treatment of malignant mesotheliomaHedy Lee Kindler
Section of Hematology/Oncology, University of Chicago, Chicago, IL 60637, USA
Semin Oncol 29:70-6. 2002.... - Pemetrexed in pancreatic cancerHedy Lee Kindler
Section of Hematology/Oncology, The University of Chicago, Chicago, IL 60637, USA
Semin Oncol 29:49-53. 2002..A 520-patient international randomized phase III trial that compares the pemetrexed/gemcitabine combination with single-agent gemcitabine is currently accruing patients... - Chemotherapy for advanced pancreatic cancer: past, present, and futureGregory Friberg
Section of Hematology/Oncology, University of Chicago, 5841 S. Maryland Avenue, MC 2115, Chicago, IL 60637-1470, USA
Curr Oncol Rep 7:186-95. 2005.... - Antiangiogenic therapies for mesotheliomaJonathan E Dowell
University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390 8852, USA
Hematol Oncol Clin North Am 19:1137-45, viii. 2005..Several clinical trials are currently evaluating the efficacy of inhibitors of angiogenesis in mesothelioma. This article details the preliminary results of these trials and future directions...